Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Feb 03, 2021 4:28pm
179 Views
Post# 32461840

RE:RE:Too bad about that "newsletter thing"

RE:RE:Too bad about that "newsletter thing"

2b7f6fab wrote: Contemplating the results in the 180 day newsletter graphic.  4 of 9 with complete response.  Then 2 more yet to be determined.  The thought occured to me those 2 are #13 and #14 who haven't yet received their 180 day treatment.  Is this possible?  If yes then we could in time actually have 6 of 9 with CR plus 2 more with partial response.  Seems like very good results, btdik.

 

The 180 day assessment that demonstrated a 4/9 CR could become a 9/9 CR post the 2nd treatment.  

With an optimized protocol, any success-limiting factor will not be found in the efficacy of the compound or technology imo, but rather in the "steady" hands of the principal investigators.  As with any new "hands-on" technology there is a learning curve...over time, as experience grows with our technology so will its success.  

<< Previous
Bullboard Posts
Next >>